2017-03-13,Apricus Biosciences Provides Corporate Update, Fourth Quarter And Full Year 2016 Financial Results
2017-03-09,Apricus Biosciences Announces Corporate Update, Fourth Quarter And Full Year 2016 Financial Results Conference Call
2017-03-08,Apricus Biosciences Announces Sale Of Ex-U.S. Vitaros Assets And Rights To Ferring Pharmaceuticals
2017-02-09,Apricus Biosciences Receives Positive Nasdaq Listing Determination
2017-02-08,Apricus Biosciences To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-18,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Mexico
2017-01-03,Apricus Biosciences Promotes Mary Naggs To Vice President, General Counsel
2016-12-27,Apricus Biosciences Announces The Launch Of Vitaros® For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals
2016-12-01,Apricus Biosciences Receives Nasdaq Compliance Notice
2016-11-29,Apricus Biosciences To Present At The 9th Annual LD Micro Main Event
2016-11-18,Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback
2016-11-08,Apricus Biosciences Provides Corporate Update And Third Quarter Financial Results
2016-11-02,Apricus Biosciences Announces Corporate Update And Third Quarter 2016 Financial Results Conference Call
2016-11-01,Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, And Apricus Biosciences
2016-10-26,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece
2016-10-20,Apricus Biosciences Announces 1-for-10 Reverse Stock Split
2016-10-12,Apricus Biosciences To Present At The 2016 BIO Investor Forum
2016-09-28,Apricus Biosciences Closes $3.7 Million Registered Direct Offering
2016-09-23,Apricus Biosciences Announces $4.6 Million Registered Direct Offering
2016-09-21,Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati
2016-09-20,Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals
2016-09-08,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina
2016-09-07,Apricus Biosciences To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-09-06,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati
2016-08-15,Apricus Biosciences Announces Completion Of Transfer Of The United Kingdom Marketing Authorization For Vitaros® To Ferring Pharmaceuticals
2016-08-10,Apricus Biosciences Announces Completion Of Transfer Of Vitaros® German Marketing Authorization To Ferring Pharmaceuticals
2016-08-04,Apricus Biosciences Provides Corporate Update And Second Quarter Financial Results
2016-08-03,Apricus Biosciences To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-01,Apricus Biosciences Announces Corporate Update And Second Quarter 2016 Financial Results Conference Call
2016-07-27,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Lebanon
2016-07-25,Apricus Biosciences Further Expands Existing Vitaros® Partnership With Ferring Pharmaceuticals In Europe And Asia
2016-07-06,Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
2016-05-09,Apricus Biosciences Provides Corporate Update And First Quarter Financial Results
2016-05-03,CORRECTING And REPLACING -- Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
2016-05-03,Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
2016-05-03,Apricus Biosciences To Announce Corporate Update And First Quarter 2016 Financial Results
2016-04-06,Apricus Biosciences Updates Strategic Corporate Objectives
2016-03-28,Apricus Reports Top-Line Phase 2b Data For Fispemifene In Symptomatic Secondary Hypogonadism
2016-03-09,Apricus Biosciences Provides Corporate Update, Fourth Quarter And Full Year 2015 Financial Results
2016-03-08,Apricus Biosciences To Present At The 28th Annual ROTH Conference
2016-03-04,Apricus Biosciences Closes $10 Million Registered Direct Offering
2016-03-02,Apricus Biosciences Announces Corporate Update, Fourth Quarter And Full Year 2015 Financial Results Conference Call
2016-03-01,Apricus Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference
2016-02-02,Apricus Biosciences To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-13,Apricus Biosciences Announces $10 Million Registered Direct Offering
2016-01-06,Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy
2015-12-01,Apricus Biosciences Confirms Clinical Strategy For Its Novel Treatment For Symptomatic Secondary Hypogonadism Fispemifene
2015-11-17,Apricus Biosciences Named To Deloitte's 2015 Technology Fast 500(TM) List Of Fastest Growing Companies In North America
2015-11-12,Apricus Biosciences To Present At The Stifel 2015 Healthcare Conference
2015-11-05,Apricus Biosciences Provides Corporate Update And Third Quarter 2015 Financial Results
2015-11-02,Apricus Biosciences Announces Corporate Update And Third Quarter 2015 Financial Results Conference Call
2015-10-28,Apricus Biosciences Completes Enrollment In Phase 2b Clinical Trial For Fispemifene In Men With Symptomatic Secondary Hypogonadism
2015-10-01,Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries
2015-09-17,Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon
2015-09-10,Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement
2015-09-10,Apricus Biosciences Enters Into License Agreement With Allergan For The U.S. Rights To Vitaros(TM)
2015-09-02,Apricus Biosciences To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Italy By Bracco SpA
2015-08-19,Apricus Biosciences Announces It Is Seeking A Global Partner For Femprox, A Novel Treatment For Female Sexual Dysfunction
2015-08-10,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Twelve Additional Countries
2015-08-05,Apricus Biosciences Provides Corporate Update And Second Quarter 2015 Financial Results
2015-08-05,Apricus Biosciences To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-07-30,Apricus Biosciences Announces Corporate Update And Second Quarter 2015 Financial Results Conference Call
2015-06-15,Apricus Biosciences Announces Last Patient Enrolled In RayVa(TM) Phase 2a Clinical Trial For Raynaud's Phenomenon In Patients With Scleroderma
2015-06-01,Apricus Biosciences Enrolls First Patients In Phase 2b Clinical Trial For Fispemifene In Men With Symptomatic Secondary Hypogonadism
2015-05-28,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In France By Laboratoires Majorelle
2015-05-11,Apricus Biosciences Provides Corporate Update And First Quarter 2015 Financial Results
2015-05-06,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Spain By Recordati
2015-05-04,Apricus Biosciences Announces Corporate Update And First Quarter 2015 Financial Results Conference Call
2015-04-28,Apricus Biosciences To Present At Two Investor Conferences In May
2015-03-16,Apricus Biosciences Provides Corporate Update And 2014 Year-End Financial Results
2015-03-09,Apricus Biosciences Announces Corporate Update And Fourth Quarter And Year-End 2014 Financial Results Conference Call
2015-03-04,Apricus Biosciences To Present At The 27th Annual Roth Conference
2015-02-11,Apricus Biosciences Announces $11 Million Registered Direct Offering With Sarissa Capital Management LP
2015-02-03,Apricus Biosciences Expands Exclusive License Agreement With An Existing Partner To Market Vitaros(R) In Select Asia-Pacific Countries
2015-02-03,Apricus Biosciences To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-29,3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
2015-01-27,Apricus Biosciences Announces Issuance Of U.S. Patent For RayVa(TM)
2015-01-12,Apricus Biosciences Announces The Appointment Of Catherine Bovenizer As Vice President Of Finance, Chief Accounting Officer
2015-01-06,Apricus Biosciences To Present At Biotech Showcase 2015
2014-12-22,Apricus Biosciences Announces Year-End 2014 Update And 2015 Plans To Advance Its Clinical Pipeline And Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
2014-12-15,Apricus Biosciences Appoints Barbara Troupin, M.D. As Chief Medical Officer
2014-12-04,Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa(TM) In Patients With Raynaud's Phenomenon
2014-12-02,Apricus Biosciences Appoints Brian T. Dorsey As Chief Development Officer
2014-11-10,Apricus Biosciences Announces Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-05,Apricus Biosciences To Present At Three Upcoming Investor Conferences In November And December Of 2014
2014-11-04,Apricus Biosciences Announces Corporate Update And Third Quarter 2014 Financial Results Conference Call
2014-11-03,Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Belgium By Sandoz
2014-10-20,Apricus Expands Development Pipeline With The In-Licensing Of U.S. Rights For Fispemifene, A Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions In Men
2014-10-13,Apricus Biosciences Announces Notice Of Allowance Of U.S. Patent Application For RayVa(TM)
2014-10-01,Apricus Biosciences To Present At The 13th Annual BIO Investor Forum
2014-09-03,Apricus Biosciences To Present At The Rodman & Renshaw 16th Annual Global Investment Conference
2014-08-18,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Germany By Hexal
2014-08-12,Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
2014-08-12,Apricus Biosciences Provides Corporate Update And Second Quarter 2014 Financial Results
2014-08-11,Apricus Biosciences Announces Appointment Of Sandford D. Smith To Board Of Directors
2014-08-08,Apricus Biosciences Announces Multi-Year Partnership With The Scleroderma Research Foundation
2014-08-06,Apricus Biosciences To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-04,Apricus Biosciences Announces Corporate Update And Second Quarter 2014 Financial Results Conference Call
2014-08-04,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Sweden By Sandoz
2014-06-16,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In The United Kingdom
2014-05-12,Apricus Biosciences Receives FDA Clearance To Begin Clinical Trial Of RayVa(TM) For Secondary Raynaud's Phenomenon
2014-05-12,Apricus Biosciences Provides Corporate Update And First Quarter 2014 Financial Results
2014-04-28,Apricus Biosciences Announces Corporate Update And First Quarter 2014 Financial Results Conference Call
2014-04-24,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Spain
2014-04-16,Apricus Biosciences' Partner In The United Kingdom Accepts First Shipment Of Vitaros(R)
2014-04-07,Apricus Biosciences And Its European Partners To Sponsor Symposium On Vitaros(R) At The European Association Of Urology (EAU) Congress, Stockholm
2014-04-03,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Luxembourg
2014-03-20,Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton As Vice President, Business Development
2014-03-17,Apricus Biosciences Provides Corporate Update And 2013 Year-End Financial Results
2014-03-10,Apricus Biosciences Announces Appointment Of Wendell Wierenga, Ph.D., To Board Of Directors
2014-03-10,Apricus Biosciences Announces Corporate Update And 2013 Year-End Financial Results Conference Call
2014-03-04,Apricus Biosciences To Present At The 26th Annual ROTH Conference
2014-02-10,Apricus And Recordati Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream - Vitaros(R) In Spain, Russia, Turkey And Other Global Territories
2014-02-04,Apricus Biosciences To Present At The 16th Annual BIO CEO & Investor Conference
2014-01-23,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Belgium
2013-12-27,Interesting APRI Put And Call Options For August 2014
2013-12-19,Apricus Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In France
2013-12-16,Apricus Expands Exclusive License Agreement With Its Partner In Germany To Market Vitaros(R) In Additional European Countries
2013-12-11,Apricus Elects Kleanthis G. Xanthopoulos, Ph.D. As New Chairman
2013-11-27,4 Stocks Under $10 in Breakout Territory
2013-11-25,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Italy
2013-11-13,Apricus Biosciences Provides Third Quarter 2013 Corporate Update
2013-11-13,Apricus And Laboratoires Majorelle Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream Vitaros(R) In France, Monaco And Certain African Countries
2013-11-05,Apricus Biosciences Announces Third Quarter 2013 Corporate Update Conference Call
2013-10-07,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Germany
2013-09-09,Apricus Biosciences Updates Presentation Time At The 2013 Stifel Nicolaus Healthcare Conference
2013-09-04,Apricus Biosciences To Present At The 2013 Stifel Nicolaus Healthcare Conference
2013-08-29,Apricus Biosciences Provides Vitaros(R) Swissmedic Update
2013-08-15,Apricus Biosciences Receives National Phase Approvals For Vitaros(R) In Ireland And The Netherlands
2013-08-12,Apricus Biosciences Reports Corporate Update
2013-08-09,Apricus Biosciences Announces Corporate Update Conference Call
2013-07-05,Biotech Stock Mailbag: Apricus, Avanir
2013-06-21,Apricus Biosciences Presents Vitaros(R) Poster At The International Symposium On Prostate, Androgens And Men's Sexual Health
2013-06-10,Apricus Biosciences Receives European Approval For Vitaros(R) For The Treatment Of Erectile Dysfunction
2013-05-23,Apricus Biosciences Prices $17.1 Million Public Offering Of Common Stock And Warrants
2013-05-22,Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants
2013-05-10,Apricus Biosciences Provides First Quarter 2013 Corporate Update
2013-05-07,Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call
2013-05-07,Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting
2013-04-18,Apricus Biosciences To Present At 2013 BIO International Convention
2013-04-01,Apricus Biosciences Announces Sale Of Non-Core Assets
2013-03-18,Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012
2013-03-18,Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer
2013-03-14,Apricus Biosciences Announces 2012 Year End Financial Results Conference Call
2013-03-14,Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries
2013-03-13,Apricus Biosciences To Present At The 25th Annual ROTH Conference
2013-03-07,Apricus Biosciences To Present At BIO-Europe Spring 2013
2013-02-06,Apricus Biosciences To Present At The 15th Annual BIO CEO & Investor Conference
2013-02-01,5 Stocks Poised for Breakouts
2013-01-03,Apricus Biosciences Announces Corporate Goals For 2013
2012-10-18,Apricus Biosciences Receives $2.5 Million Payment From Abbott Laboratories For Vitaros(R) In Canada
2012-10-01,Apricus Biosciences Announces Intent To File NDS For MycoVa(TM) In Canada
2012-09-25,Apricus Biosciences CEO To Present At Sachs Annual Biotech In Europe Investor Forum
2012-09-17,Apricus Biosciences Announces Publication In Journal Of Pharmaceutics And Drug Delivery Research
2012-09-13,Apricus Biosciences' Wholly-Owned Subsidiary NexMed (U.S.A.) And Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement To Market Vitaros(R) In The United Kingdom
2012-08-22,Apricus Biosciences' CEO To Present At The Stifel Nicolaus 2012 Healthcare Conference
2012-08-20,Apricus Biosciences Announces Podium Presentation Of Vitaros(R) Clinical Data At 2012 World Meeting On Sexual Medicine
2012-08-16,Apricus Biosciences Announces Podium Presentation Of Femprox(R) Phase III Clinical Data At 2012 World Meeting On Sexual Medicine
2012-08-11,Apricus Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
2012-03-14,Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating!
2012-02-09,Apricus Stock Gaps Down On Today's Open (APRI)
2012-01-02,Apricus Misses Promised Drug Launch Target
2011-12-09,The Worst Biotech CEO of 2011 Is ...
2011-09-23,Biotech Stock Mailbag: Medivation, Targacept
2011-09-16,Biotech Stock Mailbag: Vivus
2011-08-08,Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America
2011-07-01,Biotech Stock Mailbag: Ranking Cheap Biotechs
2011-06-29,Biotech Data Mining Comes Up Empty
2011-03-24,Apricus Biosciences Adopts Shareholder Rights Plan
2011-03-22,Apricus Biosciences Announces Poster Presentations On Progress Of PrevOnco(TM) In Combination With NexACT(R) Technology At The American Association For Cancer Research 2011 Annual Meeting
2011-03-18,Biotech Stock Mailbag: Star Scientific
2011-03-15,Apricus Biosciences Announces Formation Of Clinical Advisory Board As Part Of Its Plans To Further The Clinical Development Of Femprox(R)
2011-03-11,Biotech Stock Mailbag: Cadence Pharma
2011-03-10,Apricus Biosciences To Present At The Bio-Europe Spring 2011 Conference
2011-03-09,Apricus Biosciences Announces 2010 Year End Financial Results Conference Call
2011-03-08,Apricus Biosciences Announces Removal Of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K And Increased Cash Reserves
2011-03-01,Apricus Biosciences Announces Expanded European Patent Coverage For MycoVa(TM) For Nail Fungus
2011-02-17,Apricus Biosciences And FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion
2011-02-14,Apricus Biosciences And Neopharm Group Sign Licensing Agreement For Vitaros(R) In Israel For Up To $4.35 Million, Plus Royalties
